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Agenda
 Introduction to the Work Group – Dr. Sharon Frey
 Ebola Virus Disease – Dr. Mary Choi (CDC)
 Ebola vaccine safety, efficacy, immunogenicity – Dr. Beth-Ann Coller (Merck)
 WG perspective on vaccine data, WG next steps – Dr. Mary Choi (CDC)
Terms of Reference
 Review the available data on the rVSVΔG-ZEBOV-GP vaccine and inform 
domestic vaccine policy options for ACIP consideration
 Inform recommendations for use of the rVSVΔG-ZEBOV-GP vaccine in 
pre-exposure vaccination of healthy adults ≥ 18 years of age at 
occupational risk for exposure to Ebola virus (species Zaire ebolavirus)
Phases of Work Group Activities
 WG activities divided into 2 phases
 Phase 1
–
–
–
Review vaccination data for healthy non-pregnant, non-lactating 
adults ≥18 years of age without immunocompromising conditions
Identify U.S. populations at occupational risk for exposure to Ebola 
virus (species Zaire ebolavirus)
 Phase 2
Identify areas of further research to inform potential future 
vaccination recommendations
For more information, contact CDC
1-800-CDC-INFO (232-4636)
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